Minneapolis, MN, United States
Minneapolis, MN, United States

Medtronic plc has its principal offices in Ireland, its operational headquarters in suburban Minneapolis, Minnesota and is the world's third largest medical device company. In 2015, at the time of its relocation, Medtronic had the largest market capitalization of any company in Ireland: its market cap was about $100 billion while the market cap for CRH, Ireland’s largest indigenous business, was $18.4 billion.Medtronic operates in more than 160 countries. The company employs 85,000 people, including 5,800 scientists and engineers, pursuing research and innovation that has led to more than 28,000 patents. Wikipedia.


Time filter

Source Type

Patent
Medtronic | Date: 2017-03-15

A stent frame (10) including an annular portion (12) having first and second ends, a central longitudinal axis, and a wire portion with at least two extending posts (18) the wire portion having a generally sinusoidal series of peaks and valleys between each of the at least two extending posts; an atrial portion (14) extending from the first end of the annular portion, wherein the atrial portion includes a plurality of flares (20) that extend radially outward relative to the longitudinal axis of the annular portion; and a ventricular portion (16) extending from the second end of the annular portion, wherein the ventricular portion includes at least one flare (24) that extends radially outward relative to the longitudinal axis of the annular portion.


Implantable medical electrical leads having electrodes arranged such that a defibrillation coil electrode and a pace/sense electrode(s) are concurrently positioned substantially over the ventricle when implanted as described. The leads include an elongated lead body having a distal portion and a proximal end, a connector at the proximal end of the lead body, a defibrillation electrode located along the distal portion of the lead body, wherein the defibrillation electrode includes a first electrode segment and a second electrode segment proximal to the first electrode segment by a distance. The leads may include at least one pace/sense electrode, which in some instances, is located between the first defibrillation electrode segment and the second defibrillation electrode segment.


Patent
Medtronic | Date: 2017-04-05

A method and device for implanting a medical lead. The device includes an elongate shaft defining a major longitudinal axis and including a proximal end and a distal end. A necked portion coupled to and extending from the distal end is included, the necked portion defines a first thickness and a substantially planar surface, the necked portion being at least resiliently movable in a direction normal to the major longitudinal axis. A tip disposed at the distal end of the necked portion is included, the tip defining a second thickness greater than the first thickness


A method and medical device for determining sensing vectors that includes sensing cardiac signals from a plurality of electrodes, the plurality of electrodes forming a plurality of sensing vectors, determining a sensing vector metric in response to the sensed cardiac signals, determining a morphology metric associated with a morphology of the sensed cardiac signals, determining vector selection metrics in response to the determined sensing vector metric and the determined morphology setting, and selecting a sensing vector of the plurality of sensing vectors in response to the determined vector selection metrics.


Patent
Medtronic | Date: 2017-03-01

Overvoltage protection circuitry configured to protect internal integrated circuits within an implantable device in the presence of a high voltage event such as defibrillation or electrocautery. The circuitry allows for an internal node to rise above the voltage level of the high voltage event to insure that an overvoltage protection element is triggered, even if the voltage level of the high voltage event is below the voltage trigger level of the overvoltage protection element.


Patent
Medtronic | Date: 2017-02-08

Various embodiments of a nuclear radiation particle power converter and method of forming such power converter (10) are disclosed. In one or more embodiments, the power converter can include first and second electrodes, a three-dimensional current collector disposed between the first (12) and second (20) electrodes and electrically coupled to the first electrode, and a charge carrier separator (40) disposed on at least a portion of a surface of the three-dimensional current collector (30). The power converter can also include a hole conductor layer (50) disposed on at least a portion of the charge carrier separator and electrically coupled to the second electrode, and nuclear radiation-emitting material (60) disposed such that at least one nuclear radiation particle emitted by the nuclear radiation- emitting material is incident upon the charge carrier separator.


A machined or molded hinge design, for use with a delivery device, which allows for controlled deflection of a large diameter catheter. With embodiments in which the delivery device is employed to implant a prosthetic heart valve, deflection of the catheter allows for central alignment of the delivery system in the native annulus during deployment of the bioprosthesis.


A method and medical device for adjusting a blanking period that includes sensing cardiac signals from a plurality of electrodes, the plurality of electrodes forming a plurality of sensing vectors, determining whether to adjust a blanking period during a first operating state, advancing from the first operating state to a second operating state in response to the sensed cardiac signals, determining, while in the second operating state, whether the blanking period was adjusted while in the first operating state, and adjusting the blanking period while in the second operating state in response to the blanking period being adjusted while in the first operating state.


Grant
Agency: European Commission | Branch: H2020 | Program: IA | Phase: IoT-01-2016 | Award Amount: 25.77M | Year: 2017

ACTIVAGE is a European Multi Centric Large Scale Pilot on Smart Living Environments. The main objective is to build the first European IoT ecosystem across 9 Deployment Sites (DS) in seven European countries, reusing and scaling up underlying open and proprietary IoT platforms, technologies and standards, and integrating new interfaces needed to provide interoperability across these heterogeneous platforms, that will enable the deployment and operation at large scale of Active & Healthy Ageing IoT based solutions and services, supporting and extending the independent living of older adults in their living environments, and responding to real needs of caregivers, service providers and public authorities. The project will deliver the ACTIVAGE IoT Ecosystem Suite (AIOTES), a set of Techniques, Tools and Methodologies for interoperability at different layers between heterogeneous IoT Platforms and an Open Framework for providing Semantic Interoperability of IoT Platforms for AHA, addressing trustworthiness, privacy, data protection and security. User-demand driven interoperable IoT-enabled Active & Healthy Ageing solutions will be deployed on top of the AIOTES in every DS, enhancing and scaling up existing services, for the promotion of independent living, the mitigation of frailty, and preservation of quality of life and autonomy. ACTIVAGE will assess the socio-economic impact, the benefits of IoT-based smart living environments in the quality of life and autonomy, and in the sustainability of the health and social care systems, demonstrating the seamless capacity of integration and interoperability of the IoT ecosystem, and validating new business, financial and organizational models for care delivery, ensuring the sustainability after the project end, and disseminating these results to a worldwide audience. The consortium comprises industries, research centres, SMEs, service providers, public authorities encompassing the whole value chain in every Deployment Site.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETPROACT-01-2016 | Award Amount: 4.94M | Year: 2017

This consortium will pioneer disruptive technology for bio-electronic medicine to provide much needed therapies for cardiorespiratory and functional neurological disease. The technology implements small neural networks known as central pattern generators (CPG) to deliver fit-and-forget bio-electronic implants that respond to physiological feedback in real time, are safer, simpler, non-invasive, and have autonomy exceeding the patient lifespan. Multichannel neurons will be made to compete on analogue chips to obtain flexible motor sequences underpinned by a wide parameter space. By building large scale nonlinear optimization tools and using them to assimilate electrophysiological data, we will develop a method for automatically finding the network parameters that accurately reproduce biological motor sequences and their adaptation to multiple physiological inputs. In this way, we will have resolved the issue of programming analogue CPGs which has long been the obstacle to using neural chips in medicine. An adaptive pacemaker will be constructed, tested, validated and trialled on animal models of atrio-ventricular block and left bundle branch block to demonstrate the benefits of heart rate adaptation, beat-to-beat cardiac resynchronization and respiratory sinus arrhythmia. By providing novel therapy for arrhythmias, heart failure and their comorbidities such as sleep apnoea and hypertension, CResPace will extend patients life and increase quality of life.

Loading Medtronic collaborators
Loading Medtronic collaborators